Top

Published in:

Open Access 01-12-2015 | Research article

Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial

Authors: Rashmi Kumar, Anirban Basu, Subrata Sinha, Manoj Das, Piyush Tripathi, Amita Jain, Chandrakanta Kumar, Virendra Atam, Saima Khan, Amit Shanker Singh

Published in: BMC Infectious Diseases | Issue 1/2016

Abstract

Background

Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into cerebrospinal fluid, established neuroprotective and antiviral properties besides action on nonviral causes of AES. It has been shown to be effective in animal model of Japanese encephalitis (JE). A randomized, controlled trial of nasogastric/oral minocycline in JE and AES at a single centre in Uttar Pradesh, northern India, was therefore conducted.

Methods

Patients beyond 3 years of age - but excluding women aged 16–44 years - hospitalized with AES of < =7 days duration were enrolled and block randomized to receive nasogastric/oral minocycline or placebo suspension and followed up. Patients, study personnel and those entering data were blinded as to drug or placebo received. Primary outcome was cumulative mortality at 3 months from hospitalization. Analysis was by intention to treat.

Results

281 patients were enrolled, 140 received drug and 141 placebo. While there was no overall statistically significant difference in 3 month mortality between drug and placebo groups [RR = 0 · 83 (0 · 6-1 · 1)], there were encouraging trends in patients older than 12 years [RR = 0.70 (0.41-1.18)] and in Glasgow Outcome Score (GOS) at 3 months (χ² = 7 · 44, p = 0 · 059). These trends were further accentuated if patients dying within one day of reaching hospital were excluded [OR for 3 month mortality =0 · 70 (0 · 46-1 · 07), p = 0.090; 3 month GOS p = 0 · 028].

Conclusions

A trend towards better outcomes was observed with minocycline, especially in those patients who survived the initial day in hospital. These findings should form the basis for planning a larger study and possibly including minocycline in the initial management of AES as seen here.

Trial registration

The trial was registered with Clinical Trials Registry of India (CTRI) - CTRI/2010/091/006143

Japanese encephalitis surveillance standards. Available from: http://www.path.org/files/WHO_surveillance_standards_JE.pdf. Accessed September 10, 2014.

Economic Profile of Uttar Pradesh Available from: http://www.economywatch.com/stateprofiles/uttarpradesh/profile.htm. Accessed September 10, 2014.

Roop Kumari, Pyare L Joshi A review of Japanese encephalitis in Uttar Pradesh, India. WHO South-East Asia Journal of Public Health 2012;1(4):374-395. Ministry of Health & Family Welfare, Government of India Operational Guidelines Japanese encephalitis vaccination in India September 2010.

Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines Inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA. 1998;95:15769–74.PubMedCentralCrossRefPubMed

Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002;52:54–61.CrossRefPubMed

Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative minocycline reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Nat Acad Sci USA. 1999;96:13496–500.PubMedCentralCrossRefPubMed

Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome C release and delays progression of amyotrphic lateral sclerosis in mice. Nature. 2002;417:74–8.CrossRefPubMed

Wells J, Hurlbert J, Fehlings M, Yong VW. Neuroprotection by Minocycline facilitates significant recovery from spinal cord injury. Brain. 2003;126:1628–37.CrossRefPubMed

Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 2003;20:1017–27.CrossRefPubMed

10.

Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci. 2004;24:2182–90.CrossRefPubMed

11.

Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 2004;55:756.CrossRefPubMed

12.

Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostraital dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Nat Acad Sci USA. 2001;98:14669–74.PubMedCentralCrossRefPubMed

13.

Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase −1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington’s disease. Nat Med. 2000;6:797–801.CrossRefPubMed

14.

Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase −3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–65.CrossRefPubMed

15.

Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol. 2002;51:215–23.CrossRefPubMed

16.

Richardson-Burns SM, Tyler KL. Minocycline delays disease onset and mortality in reovirus encephalitis. Exp Neurol. 2005;192:331–9.CrossRefPubMed

17.

Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of Minocycline. JAMA. 2005;293:2003–11.CrossRefPubMed

18.

Michealis M, Kleinschmidt MC, Doerr HW, Cinalt Jr J. Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chemother. 2007;40:981–6.CrossRef

19.

Mishra MK, Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction and viral replication following Japanese encephalitis. J Neurochem. 2006;105:1582–95.CrossRef

20.

Ghosh D, Basu A. Japanese encephalitis – a pathological and clinical perspective. PLOS Neglected Tropical diseases. 2009;3:e437.PubMedCentralCrossRefPubMed

21.

Dutta K, Basu A. use of minocycline in viral infection. Indian J Med Res. 2011;133:467–70.PubMedCentralPubMed

22.

Gadkari DA, Shaikh BH. IgM antibody capture ELISA in the diagnosis of Japanese encephalitis, West Nile & dengue virus infections. Indian J Med Res. 1984;80:613–9.PubMed

23.

Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480–4.CrossRefPubMed

24.

Hulley SB, Cummings SR. Designing Clinical Research : An Epidemiologic Approach. Baltimore: Williams & Wilkins; 1992. p. 218.

25.

Amit Shanker Singh, Piyush Tripathi, Saima Firdaus Khan, Amita Jain, Virendra Atam, Rashmi Kumar Non neurological manifestations in acute encephalitis syndrome in Uttar Pradesh, India. J Neuroinfetious Dis 2014; 5: http://www.omicsonline.com/open-access/non-neurological-manifestations-in-acute-encephalitissyndrome-in-uttar-pradesh-india-2314-7326.1000143.pdf.

26.

Kumar R, Tripathi P, Singh S, Banerjee G. Clinical features of children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh. India Clinical Infectious Diseases. 2006;43:123–31.CrossRefPubMed

27.

Kumar R, Tripathi S, Tambe JJ, Arora V, Srivastava A, Nag VL. Dengue encephalopathy in children in northern India: Clinical features and comparison with nondengue. J Neurol Sciences. 2008;269:41–8.CrossRef

28.

Rathi N, Rathi A. Rickettsial Infections: Indian Perspective. Indian Pediatrics. 2010;47:157–64.CrossRefPubMed

29.

Khan SA, Dutta P, Borah J, et al. Leptospirosis presenting as acute encephalitis syndrome (AES) in Assam, India. Asian Pacific Journal of Tropical Disease. 2012;151–153.

30.

Glaser CA, Honarmand S, Anderson LJ, et al. Beyond Viruses: Clinical Profiles and Etiologies Associated with Encephalitis. Clinical Infect Dis. 2006;43:1565–77.CrossRef

31.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050444s047lbl.pdf accessed 28^th September 2014.

32.

Macdonald H, Kelly RG, Allen S, Noble JF, Kanegis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther. 1973;14:852–61.CrossRefPubMed

33.

Kang-Birken SL, Castel U, Prichard JG. Oral doxycycline for treatment of neurosyphilis in two patients infected with human immunodeficiency virus. Pharmacotherapy. 2010;30(4):119e–22e.CrossRefPubMed

34.

Dotewall L, Hagberg L. Successful oral doxycycline treatment of lyme disease associated facial palsy and meningitis. Clin Infect Dis. 1999;28:569–71.CrossRef

35.

Cunha BA. Minocycline versus Doxycycline in the Treatment of Lyme Neuroborreliosis. Clin Infect Dis. 2000;30:237–8.CrossRefPubMed

36.

Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355–66.CrossRefPubMed

Title: Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
Authors: Rashmi Kumar
Anirban Basu
Subrata Sinha
Manoj Das
Piyush Tripathi
Amita Jain
Chandrakanta Kumar
Virendra Atam
Saima Khan
Amit Shanker Singh
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-016-1385-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2016

Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trial

Determinants of treatment-related paradoxical reactions during anti-tuberculosis therapy: a case control study

Brucellosis in pregnant women from Pakistan: an observational study

Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens

End TB strategy: the need to reduce risk inequalities

Complicated malaria symptoms associated with Plasmodium vivax among patients visiting health facilities in Mendi town, Northwest Ethiopia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials